Calithera Biosciences (CALA) Competitors

$0.0002 0.00 (0.00%)

As of 05/22/2026 02:33 PM Eastern

CALA vs. GNCA, SMFL, GNCAQ, SYRS, and CMRA

Should you buy Calithera Biosciences stock or one of its competitors? MarketBeat compares Calithera Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calithera Biosciences include Genocea Biosciences (GNCA), Smart for Life (SMFL), Genocea Biosciences (GNCAQ), Syros Pharmaceuticals (SYRS), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical products" industry.

How does Calithera Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.05, indicating that its stock price is 205% less volatile than the broader market.

0.6% of Genocea Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Genocea Biosciences has higher revenue and earnings than Calithera Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

Calithera Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
Calithera Biosciences	N/A	N/A	N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Calithera Biosciences	Neutral

Summary

Genocea Biosciences and Calithera Biosciences tied by winning 4 of the 8 factors compared between the two stocks.

How does Calithera Biosciences compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 6.6% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Smart for Life has higher revenue and earnings than Calithera Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smart for Life	$11.11M	0.00	-$22.68M	-$14.48	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
Smart for Life	Neutral
Calithera Biosciences	Neutral

Smart for Life has a beta of 13.95, indicating that its share price is 1,295% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.05, indicating that its share price is 205% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Smart for Life	N/A	N/A	N/A
Calithera Biosciences	N/A	N/A	N/A

Summary

Smart for Life beats Calithera Biosciences on 6 of the 6 factors compared between the two stocks.

How does Calithera Biosciences compare to Genocea Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Calithera Biosciences has a beta of -1.05, suggesting that its share price is 205% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Genocea Biosciences	N/A	N/A	N/A

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Calithera Biosciences	Neutral
Genocea Biosciences	Neutral

Summary

Calithera Biosciences and Genocea Biosciences tied by winning 1 of the 2 factors compared between the two stocks.

How does Calithera Biosciences compare to Syros Pharmaceuticals?

Calithera Biosciences (NASDAQ:CALA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Calithera Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Calithera Biosciences has higher earnings, but lower revenue than Syros Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Calithera Biosciences	Neutral
Syros Pharmaceuticals	Neutral

Calithera Biosciences has a beta of -1.05, meaning that its stock price is 205% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Summary

Calithera Biosciences and Syros Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Calithera Biosciences compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Comera Life Sciences has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Calithera Biosciences has a beta of -1.05, indicating that its stock price is 205% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Calithera Biosciences	N/A	N/A	N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company	Overall Sentiment
Comera Life Sciences	Neutral
Calithera Biosciences	Neutral

Comera Life Sciences has higher revenue and earnings than Calithera Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A

Summary

Comera Life Sciences beats Calithera Biosciences on 3 of the 4 factors compared between the two stocks.

Get Calithera Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CALA vs. The Competition

Export

Metric	Calithera Biosciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1K	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	0.00	1.46	21.00	25.66
Price / Sales	N/A	119.63	562.18	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	N/A	7.59	10.41	7.14
Net Income	-$39.65M	-$3.64M	$3.57B	$335.98M
7 Day Performance	N/A	3.01%	6.40%	4.11%
1 Month Performance	N/A	76.62%	3.54%	2.52%
1 Year Performance	N/A	126.61%	34.14%	35.04%

Calithera Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALA Calithera Biosciences	N/A	$0.00 flat	N/A	-66.7%	$1K	N/A	N/A	60
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70	Gap Up
SMFL Smart for Life	N/A	$0.00 flat	N/A	-64.0%	$6K	$11.11M	N/A	110	Gap Up
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	$5K	N/A	N/A	70
SYRS Syros Pharmaceuticals	N/A	$0.00 flat	N/A	-98.7%	$5K	$386K	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calithera Biosciences (CALA) Competitors

CALA vs. GNCA, SMFL, GNCAQ, SYRS, and CMRA

How does Calithera Biosciences compare to Genocea Biosciences?

Summary

How does Calithera Biosciences compare to Smart for Life?

Summary

How does Calithera Biosciences compare to Genocea Biosciences?

Summary

How does Calithera Biosciences compare to Syros Pharmaceuticals?

Summary

How does Calithera Biosciences compare to Comera Life Sciences?

Summary

CALA vs. The Competition

Calithera Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Calithera Biosciences (CALA) Competitors

CALA vs. GNCA, SMFL, GNCAQ, SYRS, and CMRA

How does Calithera Biosciences compare to Genocea Biosciences?

Which has more risk & volatility, GNCA or CALA?

Do insiders and institutionals hold more shares of GNCA or CALA?

Which has preferable earnings & valuation, GNCA or CALA?

Is GNCA or CALA more profitable?

Does the media prefer GNCA or CALA?

Summary

How does Calithera Biosciences compare to Smart for Life?

Do institutionals and insiders believe in SMFL or CALA?

Which has better earnings & valuation, SMFL or CALA?

Does the media favor SMFL or CALA?

Which has more volatility and risk, SMFL or CALA?

Is SMFL or CALA more profitable?

Summary

How does Calithera Biosciences compare to Genocea Biosciences?

Which has more volatility & risk, CALA or GNCAQ?

Which has stronger valuation and earnings, CALA or GNCAQ?

Is CALA or GNCAQ more profitable?

Does the media prefer CALA or GNCAQ?

Summary

How does Calithera Biosciences compare to Syros Pharmaceuticals?

Do institutionals and insiders have more ownership in CALA or SYRS?

Is CALA or SYRS more profitable?

Which has preferable valuation and earnings, CALA or SYRS?

Does the media favor CALA or SYRS?

Which has more volatility and risk, CALA or SYRS?

Summary

How does Calithera Biosciences compare to Comera Life Sciences?

Which has more risk and volatility, CMRA or CALA?

Is CMRA or CALA more profitable?

Does the media favor CMRA or CALA?

Which has stronger earnings and valuation, CMRA or CALA?

Summary

CALA vs. The Competition

Calithera Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools